Jump Financial’s Pliant Therapeutics PLRX Stock Holding History

Jump Financial’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,473	Closed	-$29.5K	–	2113
2025 Q2	$29.5K	Buy	+25,473	New	+$36K	﹤0.01%	1710
2025 Q1	–	Sell	-19,402	Closed	-$256K	–	1919
2024 Q4	$256K	Buy	+19,402	New	+$265K	0.01%	1386
2023 Q4	–	Sell	-78,768	Closed	-$1.37M	–	2135
2023 Q3	$1.37M	Sell	78,768 -24,742	-24%	-$429K	0.05%	522
2023 Q2	$1.88M	Buy	103,510 +37,643	+57%	+$891K	0.07%	414
2023 Q1	$1.75M	Buy	65,867 +22,988	+54%	+$654K	0.07%	401
2022 Q4	$829K	Sell	42,879 -3,322	-7%	-$69.4K	0.04%	565
2022 Q3	$965K	Buy	46,201 +13,701	+42%	+$262K	0.04%	637
2022 Q2	$260K	Buy	32,500 +19,835	+157%	+$127K	0.01%	1140
2022 Q1	$88K	Buy	12,665 +2,465	+24%	+$25.2K	﹤0.01%	1428
2021 Q4	$138K	Buy	+10,200	New	+$162K	0.01%	1176

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jump Financial's PLRX Position: Q3 2025 in Review

Jump Financial sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 25,473 shares — an estimated $29.5K sold.

Jump Financial first reported a position in PLRX in Q4 2021 and held it in 10 quarters. The position peaked at $1.88M in Q2 2023. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

Jump Financial reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
Jump Financial sold 25,473 Pliant Therapeutics shares in Q3 2025, an estimated $29.5K.
Jump Financial first reported a position in Pliant Therapeutics in Q4 2021 and held it in 10 quarters.
Jump Financial's Pliant Therapeutics position peaked at $1.88M in Q2 2023.
99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Jump Financial's 13F filing for Q3 2025, filed 13 Nov 2025.